Xgeva off-label and for prostate cancer
Xgeva(denosumab) is FDA indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. In the pivotal study, denosumab was superior to zoledronic acid in delaying or preventing skeletal related events(SRE), which are essentially fractures, in patients with breast cancer metastatic to bone and was generally well tolerated. With the convenience of a under the skin injection and no requirement for monitoring
Read more